Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study.

Ellen N BehrendCynthia R WardVictor ChukwuAudrey K CookCarla KrohPatty LathanJacky MayThomas SchermerhornJ Catharine Scott-MoncrieffRebecca Voth

Published in: Journal of the American Veterinary Medical Association (2024)

Velagliflozin improved glycemic parameters and clinical signs in diabetic cats. Velagliflozin provides an alternative to insulin as a stand-alone treatment of diabetic cats.

Keyphrases

type diabetes
glycemic control
wound healing
physical activity
insulin resistance
ionic liquid
metabolic syndrome
combination therapy